Literature DB >> 7389235

Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

L G Sultatos, B H Dvorchik, E S Vesell, D G Shand, R A Branch.   

Abstract

Mesh：

Substances：

Year:  1980        PMID： 7389235     DOI： 10.2165/00003088-198005030-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  20 in total

1.  Unaltered metabolism of antipyrine and tolbutamide in fasting man.

Authors:  M M Reidenberg; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

2.  Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.

Authors:  G W Hepner; E S Vesell; A Lipton; H A Harvey; G R Wilkinson; S Schenker
Journal:  J Lab Clin Med       Date:  1977-09

3.  Effect of vitamin C supplement on antipyrine disposition in man.

Authors:  J B Houston
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

4.  Failure of cola nut chewing to alter antipyrine disposition in normal male subjects from a small town in South Central Pennsylvania.

Authors:  E S Vesell; C A Shively; G T Passananti
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

5.  Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.

Authors:  G W Hepner; E S Vesell
Journal:  N Engl J Med       Date:  1974-12-26       Impact factor: 91.245

6.  Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors:  D Perrier; M Gibaldi
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

7.  Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.

Authors:  S Lindgren; P Collste; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

8.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

9.  The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Authors:  C J Roberts; L Jackson; M Halliwell; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

10.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059
View more
  17 in total

1.  An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.

Authors:  T Edeki; A Johnston; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Plasma antipyrine half-life can be determined from urine data.

Authors:  J O Atiba; G Taylor; R A Pershe; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

3.  A comparison of the effects of a macrobiotic diet and a Western diet on drug metabolism and plasma lipids in man.

Authors:  P S Wissel; M Denke; C E Inturrisi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics.

Authors:  J McEwen; M E McMurdo; T A Moreland
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Jul-Sep       Impact factor: 2.441

Review 5.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

6.  Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.

Authors:  M B Penno; E S Vesell
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

Review 7.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

8.  Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6 beta-hydroxycortisol excretion and plasma gamma-glutamyltranspeptidase activity.

Authors:  T A Moreland; B K Park; G W Rylance
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

9.  Antipyrine kinetics in undernourished diabetics.

Authors:  J C Shobha; T C Raghuram; A D Kumar; K Krishnaswamy
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Estimating the clearance of amylobarbitone from a single plasma measurement.

Authors:  K Bachmann
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.